Intensive Drug Therapy for Ischemic Stroke

To observe the safety and efficacy of intensive drug therapy for ischemic stroke patients.Patients with acute stroke caused by intracranial arterial stenosis (stenosis rate ≥70%) were enrolled and accept dual antiplatelet therapy (DAPT) (aspirin 100 mg/d and clopidogrel 75 mg/d for 90 days, followed by aspirin 100 mg/d for long term) under the guidance of platelet function analysis (Verifynow) combined with the intensive statin therapy (40 mg/d for 14 days, followed by 20 mg/d for long term).

Inclusion Criteria:Age between 35 and 80 years;Onset <72 hours;New-onset ischemic stroke confirmed by skull magnetic resonance diffusion weighted imaging (MR-DWI);Severe ICAS (stenosis ≥70%) indicated by time-of-flight magnetic resonance angiography (TOF-MRA).Exclusion Criteria:Ischemic stroke caused by other etiological factors (e.g., cardio-embolism, arterial dissection, vasculitis, etc.);Post-infarction hemorrhagic transformation and intraplaque hemorrhage as indicated by imaging examination;Contraindications to aspirin, clopidogrel, or atorvastatin;Intracranial hemorrhage within 3 months and a recent history of surgery or trauma;Severe organ impairment, liver insufficiency, and renal insufficiency;Complicated with tumors or hemorrhagic diseases;Use of drugs forbidden to use in combination after onset, including other antiplatelet drugs, anticoagulants, thrombolytic drugs, and drugs affecting antiplatelet agents and statin metabolism.